StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)

Close on Nov 17, 2026Market cap $28.91MP/E –Yield –

Earnings

Aytu BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 12, 2026
Q1 FY2027 · estimated, during market hours
Revenue, Q4 FY2026
$16.10M
+6.6% on a year earlier
EPS, Q4 FY2026
$0.00
-$2.92 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Aytu BioPharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2027ended Sep 30, 2026Nov 12, 2026Expected––––
Q4 FY2026ended Jun 30, 2026Sep 22, 2026during market hours$16.10M+6.6%$0.00Release
Q3 FY2026ended Mar 31, 2026May 13, 2026during market hours$12.40M-33.0%-$0.53Release
Q2 FY2026ended Dec 31, 2025Feb 3, 2026during market hours$15.20M-6.2%-$1.05Release
Q1 FY2026ended Sep 30, 2025Nov 13, 2025during market hours$13.90M-16.3%-$0.08Release
Q4 FY2025ended Jun 30, 2025Sep 23, 2025during market hours$15.10M-16.1%-$2.92Release
Q3 FY2025ended Mar 31, 2025May 14, 2025during market hours$18.50M+2.8%$0.21Release
Q2 FY2025ended Dec 31, 2024Feb 12, 2025during market hours$16.20M-29.3%-$0.26Release
Q1 FY2025ended Sep 30, 2024Nov 13, 2024during market hours$16.60M-24.9%-$0.15Release
Q4 FY2024ended Jun 30, 2024Sep 26, 2024during market hours$18.00M-41.4%-$0.82Release
Q3 FY2024ended Mar 31, 2024May 15, 2024during market hours$18.00M-20.7%-$0.52Release
Q2 FY2024ended Dec 31, 2023Feb 14, 2024during market hours$22.90M-12.9%-$0.04Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Aytu BioPharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Aytu BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Aytu BioPharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. Results
  10. Update
  11. Update
  12. Update
  13. Update
  14. Update
  15. Results

See a number that looks wrong?